Role of Blood Pressure Management in Stroke Prevention: A Systematic Review and Network Meta-Analysis of 93 Randomized Controlled Trials
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background and Purpose: The present study aimed to compare the efficacy and tolerability of different blood pressure (BP)-lowering strategies. Methods: Randomized controlled trials that compared various antihypertensive treatments and stroke outcomes were included. Eligible trials were categorized into three scenarios: single or combination antihypertensive agents against placebos; single or combination agents against other agents; and different BP-lowering targets. The primary efficacy outcome was the risk reduction pertaining to strokes. The tolerability outcome was the withdrawal of drugs, owing to drug-related side effects (PROSPERO registration number CRD42018118454 [20/12/2018]). Results: The present study included 93 trials (average follow-up duration, 3.3 years). In the pairwise analysis, angiotensin-converting enzyme inhibitors (ACEis) and beta-blockers (BBs) were inferior to calcium channel blockers (CCBs) (odds ratio [OR], 1.123; 95% confidence interval [CI], 1.008 to 1.252) (OR, 1.261; 95% CI, 1.116 to 1.425) for stroke prevention, BB was inferior to angiotensin II receptor blockers (ARB) (OR, 1.361; 95% CI, 1.142 to 1.622), and diuretics were superior to ACEi (OR, 0.871; 95% CI, 0.771 to 0.984). The combination of ACEi+CCB was superior to ACEi+diuretic (OR, 0.892; 95% CI, 0.823 to 0.966). The network meta-analysis confirmed that diuretics were superior to BB (OR, 1.34; 95% CI, 1.11 to 1.58), ACEi+diuretic (OR, 1.47; 95% CI, 1.02 to 2.08), BB+CCB (OR, 2.05; 95% CI, 1.05 to 3.79), and renin inhibitors (OR, 1.87; 95% CI, 1.25 to 2.75) for stroke prevention. Regarding the tolerability profile, the pairwise analysis revealed that ACEi was inferior to CCB and less tolerable, compared to the other treatments. Conclusions: Monotherapy using diuretics, CCB, or ARB, and their combinations could be employed as first-line treatments for stroke prevention in terms of efficacy and tolerability.
Abstract
Background and Purpose: The present study aimed to compare the efficacy and tolerability of different blood pressure (BP)-lowering strategies. Methods: Randomized controlled trials that compared various antihypertensive treatments and stroke outcomes were included. Eligible trials were categorized into three scenarios: single or combination antihypertensive agents against placebos; single or combination agents against other agents; and different BP-lowering targets. The primary efficacy outcome was the risk reduction pertaining to strokes. The tolerability outcome was the withdrawal of drugs, owing to drug-related side effects (PROSPERO registration number CRD42018118454 [20/12/2018]). Results: The present study included 93 trials (average follow-up duration, 3.3 years). In the pairwise analysis, angiotensin-converting enzyme inhibitors (ACEis) and beta-blockers (BBs) were inferior to calcium channel blockers (CCBs) (odds ratio [OR], 1.123; 95% confidence interval [CI], 1.008 to 1.252) (OR, 1.261; 95% CI, 1.116 to 1.425) for stroke prevention, BB was inferior to angiotensin II receptor blockers (ARB) (OR, 1.361; 95% CI, 1.142 to 1.622), and diuretics were superior to ACEi (OR, 0.871; 95% CI, 0.771 to 0.984). The combination of ACEi+CCB was superior to ACEi+diuretic (OR, 0.892; 95% CI, 0.823 to 0.966). The network meta-analysis confirmed that diuretics were superior to BB (OR, 1.34; 95% CI, 1.11 to 1.58), ACEi+diuretic (OR, 1.47; 95% CI, 1.02 to 2.08), BB+CCB (OR, 2.05; 95% CI, 1.05 to 3.79), and renin inhibitors (OR, 1.87; 95% CI, 1.25 to 2.75) for stroke prevention. Regarding the tolerability profile, the pairwise analysis revealed that ACEi was inferior to CCB and less tolerable, compared to the other treatments. Conclusions: Monotherapy using diuretics, CCB, or ARB, and their combinations could be employed as first-line treatments for stroke prevention in terms of efficacy and tolerability.
참고문헌 (28)
- Krishnamurthi RV, "Global, regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the global burden of disease study 2017", Neuroepidemiology, 54, pp.171~179 (2020)
- Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
- Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis", Lancet, 387, pp.957~967 (2016)
- Katsanos AH, "Blood pressure reduction and secondary stroke prevention : a systematic review and metaregression analysis of randomized clinical trials", Hypertension, 69, pp.171~179 (2017)
- Reboussin DM, "Systematic review for the 2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
- Jeffers BW, "Efficacy of calcium channel blockers versus other classes of antihypertensive medication in the treatment of hypertensive patients with previous stroke and", or coronary artery disease : a systematic review and meta-analysis, 2017, pp.24, e68~e80
- Salanti G, "Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool", Res Synth Methods, 3, pp.80~97 (2012)
- Jansen JP, "Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making : report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices : part 1", Value Health, 14, pp.417~428 (2011)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", PLoS Med, 6, pp.e1000097~ (2009)
- Hutton B, "The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions : checklist and explanations", Ann Intern Med, 162, pp.777~784 (2015)
- Law MR, "Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies", BMJ, 338, pp.b1665~ (2009)
- "Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0" (2020)[URL]
- Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
- Biondi-Zoccai G, "Network meta-analysis for evidence synthesis : what is it and why is it posed to dominate cardiovascular decision making", Int J Cardiol, 182, pp.309~314 (2015)
- Dias S, "Checking consistency in mixed treatment comparison meta-analysis", Stat Med, 29, pp.932~944 (2010)
- Lu G, "Assessing evidence inconsistency in mixed treatment comparisons", J Am Stat Assoc, 101, pp.447~459 (2006)
- Higgins JP, "Consistency and inconsistency in network meta-analysis : concepts and models for multi-arm studies", Res Synth Methods, 3, pp.98~110 (2012)
- Salanti G, "Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis : an overview and tutorial", J Clin Epidemiol, 64, pp.163~171 (2011)
- Chaimani A, "Graphical tools for network meta-analysis in STATA", PLoS One, 8, pp.e76654~ (2013)
- Mukete BN, "Longterm anti-hypertensive therapy and stroke prevention : a meta-analysis", Am J Cardiovasc Drugs, 15, pp.243~257 (2015)
- SPS3 Study Group, "Blood-pressure targets in patients with recent lacunar stroke : the SPS3 randomised trial", Lancet, 382, pp.507~515 (2013)
- Park JM, "Intensive blood pressure control may not be safe in subacute ischemic stroke by intracranial atherosclerosis : a result of randomized trial", J Hypertens, 36, pp.1936~1941 (2018)
- James PA, "2014 Evidence-based guideline for the management of high blood pressure in adults : report from the panel members appointed to the Eighth Joint National Committee(JNC 8)", JAMA, 311, pp.507~520 (2014)
- Weiss J, "Benefits and harms of intensive blood pressure treatment in adults aged 60 years or older : a systematic review and meta-analysis", Ann Intern Med, 166, pp.419~429 (2017)
- SoRelle R, "National Heart, Lung, and Blood Institute halts part of antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)", Circulation, 101, pp.E9025~ (2000)
- Xie XX, "Blood pressure lowering and stroke events in type 2 diabetes : a network meta-analysis of randomized controlled trials", Int J Cardiol, 208, pp.141~146 (2016)
- Rouse B, "Network meta-analysis : an introduction for clinicians", Intern Emerg Med, 12, pp.103~111 (2017)